Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00754494 · ClinicalTrials.gov registry record · Phase 2
Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT00754494: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00754494 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 45 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00754494, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
This randomized phase II trial is studying how well erlotinib hydrochloride works in treating patients with stage I-III colorectal cancer or adenoma. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Erlotinib hydrochloride may also stop tumors from growing or coming back
Interventions
- OTHER laboratory biomarker analysis
- OTHER placebo
- DRUG erlotinib hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2008-07 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00754494
The ClinicalTrials.gov registry entry for NCT00754494 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00754494 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00754494 about?
NCT00754494 is a clinical study titled "Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma". This randomized phase II trial is studying how well erlotinib hydrochloride works in treating patients with stage I-III colorectal cancer or adenoma. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tu...
What is the current status of trial NCT00754494?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2008-07. Estimated completion is 2013-09.
What interventions are being tested in trial NCT00754494?
The interventions under investigation include: laboratory biomarker analysis (OTHER), placebo (OTHER), erlotinib hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00754494?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.